H.C. Wainwright raised the firm’s price target on Genfit to $13 from $11 and keeps a Buy rating on the shares after the company’s partner Ipsen announced the FDA has granted accelerated approval of Iqirvo once-daily for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid. The firm says Iqirvo has a favorable label to support trial and uptake.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GNFT:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue